C07J 17/00
Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero
Official title: Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton (cardanolide, bufanolide C07J19/00)
C07J17/00 (Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero) appears on 559 US grants and 453 published applications in this corpus.
Search patents in C07J- Granted patents
- 559
- Published applications
- 453
- Assignees
- 342
- Inventors
- 1,420
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 11 | 0 |
| 1977 | 17 | 0 |
| 1978 | 18 | 0 |
| 1979 | 7 | 0 |
| 1980 | 14 | 0 |
| 1981 | 10 | 0 |
| 1982 | 13 | 0 |
| 1983 | 6 | 0 |
| 1984 | 6 | 0 |
| 1985 | 8 | 0 |
| 1986 | 11 | 0 |
| 1987 | 6 | 0 |
| 1988 | 2 | 0 |
| 1989 | 8 | 0 |
| 1990 | 9 | 0 |
| 1991 | 4 | 0 |
| 1992 | 8 | 0 |
| 1993 | 8 | 0 |
| 1994 | 6 | 0 |
| 1995 | 13 | 0 |
| 1996 | 12 | 0 |
| 1997 | 29 | 0 |
| 1998 | 22 | 0 |
| 1999 | 10 | 0 |
| 2000 | 10 | 0 |
| 2001 | 9 | 1 |
| 2002 | 5 | 7 |
| 2003 | 8 | 21 |
| 2004 | 6 | 15 |
| 2005 | 9 | 12 |
| 2006 | 6 | 17 |
| 2007 | 6 | 9 |
| 2008 | 4 | 5 |
| 2009 | 4 | 9 |
| 2010 | 6 | 16 |
| 2011 | 3 | 20 |
| 2012 | 8 | 18 |
| 2013 | 9 | 13 |
| 2014 | 13 | 23 |
| 2015 | 14 | 25 |
| 2016 | 21 | 20 |
| 2017 | 19 | 26 |
| 2018 | 15 | 21 |
| 2019 | 24 | 31 |
| 2020 | 23 | 25 |
| 2021 | 21 | 37 |
| 2022 | 16 | 21 |
| 2023 | 11 | 22 |
| 2024 | 11 | 20 |
| 2025 | 16 | 15 |
| 2026 | 4 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- C17, C20, and C21 substituted neuroactive steroids and their methods of use16 Jun 2026US 12,655,175 B2Sage Therapeutics, Inc.
- Composition containing nicotinamide mononucleotide and mogroside, and application thereof31 Mar 2026US 12,589,107 B2Beijing Hebabiz Biotechnology Co., Inc.
- Mogrosides and uses of the same24 Feb 2026US 12,557,831 B2The Coca-Cola Company
- Oxysterols and methods of use thereof3 Feb 2026US 12,540,157 B2Sage Therapeutics, Inc.
- Process for preparing (3α,5α)-3-hydroxy-3-methyl-pregnan-20-one (Ganaxolone)9 Dec 2025US 12,492,221 B2Industriale Chimica S.R.L.
- Oxysterols and methods of use thereof8 Oct 2026US 2026/0308197 A1Sage Therapeutics, Inc.
- Process For The Purification Of 2-Methoxyestradiol From 4- Methoxyestradiol And Intermediates Of The Process24 Sep 2026US 2026/0285896 A1Industriale Chimica S.R.L.
- Oxysterols and methods of use thereof7 May 2026US 2026/0125416 A1Sage Therapeutics, Inc.
- GPX4 Inhibitors and Senolytic Compounds and Uses Thereof8 Jan 2026US 2026/0007689 A1Rubedo Life Sciences, Inc.
- Mogroside Biocatalysis Methods20 Nov 2025US 2025/0354190 A1The Coca-Cola Company
Most cited
By later US patents
- Saponin adjuvant520US 5,057,540 ACambridge Biotech Corporation · 1991
- 4-Aza-17.beta.-substituted-5.alpha.-androstan-3-one-reductase inhibitors159US 4,377,584 AMerck & Co., Inc. · 1983
- Anti-estrogenic compounds and compositions119US 5,395,842 AEndorecherche, Inc. · 1995
- Neuroactive steroids of the androstane and pregnane series114US 5,925,630 ACoCensys, Inc. · 1999
- 3,20-Dioxo-1,4-pregnadiene-17.alpha.-ol 17-aromatic heterocycle carboxylates112US 4,472,393 ASchering Corporation · 1984